Immunovant (NASDAQ:IMVT) PT Raised to $51.00 at Bank of America
Immunovant (NASDAQ:IMVT – Free Report) had its target price upped by Bank of America from $49.00 to $51.00 in a report released on Thursday morning, Benzinga reports. Bank of America currently has a buy rating on the stock. IMVT has been the subject of several other reports. Raymond James upgraded shares of Immunovant from a […]
More Stories
CAP Partners LLC Grows Stock Holdings in TCW Flexible Income ETF (NYSEARCA:FLXR)
CAP Partners LLC increased its position in shares of TCW Flexible Income ETF (NYSEARCA:FLXR – Free Report) by 8.5% in...
CAP Partners LLC Purchases 1,599 Shares of JPMorgan Ultra-Short Income ETF (NYSEARCA:JPST)
CAP Partners LLC grew its position in JPMorgan Ultra-Short Income ETF (NYSEARCA:JPST – Free Report) by 12.4% during the 3rd...
Colony Family Offices LLC Boosts Stock Holdings in iShares Core MSCI EAFE ETF (BATS:IEFA)
Colony Family Offices LLC increased its stake in iShares Core MSCI EAFE ETF (BATS:IEFA – Free Report) by 1.5% in...
Strengthening Families & Communities LLC Buys 290 Shares of Motorola Solutions, Inc. (NYSE:MSI)
Strengthening Families & Communities LLC boosted its stake in shares of Motorola Solutions, Inc. (NYSE:MSI – Free Report) by 7.5%...
CAP Partners LLC Boosts Stake in Shopify Inc. (NYSE:SHOP)
CAP Partners LLC boosted its stake in shares of Shopify Inc. (NYSE:SHOP – Free Report) (TSE:SHOP) by 1.4% during the...
Kenvue Inc. (NYSE:KVUE) is Equity Investment Corp’s 5th Largest Position
Equity Investment Corp increased its stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 0.0% in the third...